SN BioScience and Boryung Announce the Licensing Agreement on Generic Version of Abraxane

• First Generic of Abraxane in Korea, World 4th Commercial Scale-Up
• Global tech-transfer expected to US, Japan, and Europe

SEONGNAM, South Korea, Jan. 26, 2023 /PRNewswire/ -- SN BioScience (CEO Park Young-hwan) and Boryeong (CEO Jang Doo-hyun) signed a domestic manufacturing technology transfer and co-development contract for the albumin nanoparticle anticancer drug (code name: SNA-001) developed by SN BioScience for the first time in Korea and the fourth time in the world. Through this contract, Boryeong will have exclusive manufacturing and distribution rights in Korea for "SNA-001." SN BioScience will receive milestones and double-digit royalties according to the development stage. SN BioScience also signed a domestic distribution agreement with Boryeong in February 2021 for SNB-101, a polymer nanoparticle new drug, and expects a variety of cooperations in the field of anticancer drugs in the future.

"SNA-001" is a product that electrostatically binds cytotoxic anticancer drugs to albumin using albumin present in human blood as a drug carrier. Abraxane is a global blockbuster first developed by Abraxis BioScience Inc (acquired by Celgene who became a subsidiary of BMS), with sales of $1.5 billion worldwide in 2020.

Albumin has been studied as a carrier that delivers various drugs into cells through electrostatic or chemical bonds with excellent biocompatibility as about 66,000 Dalton of drug transport protein in the blood. Despite the advantages, there has been challenges in commercial scale-up. Even BMS, the original manufacturer, has gone through global shortages from 2019 to 2021 due to manufacturing/quality issues. Only a few companies around the world, such as Teva, have succeeded in scale-up production to date. Based on the commercial scale-up technology for nanoparticle drugs accumulated through SNB-101 (API: SN-38, firtecan), a nanoparticle anticancer drug that has already entered phase 1, SN BioScience has completed the development of a commercial-scale manufacture process for the Abraxane's generic for the fourth time in the world. SN BioScience developed a superior manufacturing process with a yield of more than 90% and a particle size deviation of less than 7%, which is evaluated as having excellent quality and reproducibility compared to products of competitors with a yield of about 70 to 80%.

SNA-001 showed excellent efficacy in solid cancer animal models in non-clinical studies. In the characterization of the in vivo behavior of nanoparticles, it was suitable for key evaluation indicators such as free and encapsulated drug concentrations and drug accumulation in major organs.

Based on the above, SN BioScience is discussing the technology transfer with global leading pharmaceutical companies in the United States, Japan, and Europe, while on the other hand, it is discovering new indications by applying albumin-based nanoparticle platforms to various anticancer drugs. The company is also planning to file phase 1 IND for two to three new nanoparticle anticancer drugs in the second half of this year.

About SN BioScience Inc

SN BioScience is a biotech company established in May 2017, a drug delivery system R&D company specialized in anti-cancer drugs, and is located in the 2nd Pangyo Techno Valley in Seongnam-si, Gyeonggi-do, Korea. SN BioScience was founded by pharmaceutical R&D experts, world-class bio-polymer research professors, and clinical professors. From the beginning of its establishment, it has been developing nanoliposomes and nanoparticle drug carriers based on drug metrology and pharmacokinetics. The main pipelines include polymeric nanoparticle anticancer drugs (on-going phase I in Korea) and albumin nanoparticle anticancer drugs (phase I IND filed).

About Boryung Co., Ltd

Founded in 1957, Boryeong Co., Ltd. is a top-tier pharmaceutical company in Korea that manufactures and sells drugs for chronic diseases such as hypertension, diabetes, brain disease, and anticancer, with sales of about USD 550 million in 2022. In addition, the company has produced various and successful research results, including Kanarb Tab., a new drug for high blood pressure, and has the highest market share in Korea, especially in the field of anticancer drugs.

SOURCE SN BioScience Inc